Protease inhibitors and prevention of cross resistance.
Levin
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002219:Carbamates; D016049:Didanosine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019469:Indinavir; D007546:Isoquinolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019259:Lamivudine; D019888:Nelfinavir; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D019258:Saquinavir; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000998:Antiviral Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011804:Quinolines; D013449:Sulfonamides; D019259:Lamivudine; D015215:Zidovudine; C095108:amprenavir; D019469:Indinavir; D016047:Zalcitabine; D019888:Nelfinavir; D016049:Didanosine; D019258:Saquinavir